Abstract：【Objective】 To analyze the expression levels and significance of mismatch repair (MMR) proteins in patients with endometrial cancer (EC). 【Methods】 A total of 196 samples of EC tissues retained in the pathology department of our hospital from January 2013 to January 2016 were collected as subjects. The expression levels of four mismatch repair (MMR) proteins: MutL protein homolog 1 (MLH1), Postmeiotic protein isolate 2 (PMS2), MutS protein homolog 2 (MSH2) and MutS protein homolog 6 (MSH6) were detected by immunohistochemistry, and the relationship between their expressions and clinicopathological characteristics of the patients was analyzed. Meanwhile the survival of the patients was observed as well. 【Results】 Among the 196 EC samples, the proportion of simultaneous expressions of four MMR proteins of MLH1, PMS2, MSH2 and MSH6 was 72.45% (142/196) and the expression of MMR protein deletion accounted for 27.55% (54/196). The deletion of MMR proteins were related to age, cell differentiation degree, myometrial infiltration degree, tumor site and lymph node metastasis of EC patients (P<0.05),while the lack of MMR protein expressions were not significantly correlated with combined basic diseases, tumor pathological types and FIGO stage (P>0.05). The median survival time and 3-year survival rate in simultaneous expressions of MMR proteins were 37.89 months and 90.14% (128/142), respectively, and the median survival time and 3-year survival rate in deletion expressions of MMR proteins were 37.56 months and 88.89% (48/54), respectively. There was no statistically significant difference in the median survival time between patients with simultaneous expressions of MMR proteins and patients with deletion expressions of MMR proteins (P>0.05). 【Conclusion】 The deletion expressions of MMR proteins are associated with the occurrence and development of EC. The deletion rates of MMR protein expressions are significantly increased among patients with age ≤50 years old, low differentiation,≥50% myometrial infiltration, involvement of lower uterine segment and lymph node metastasis. Deletion expressions of MMR proteins may be associated with poor prognosis of patients.
2020, Vol. 37 
